Research Ayala's ex-BMS drug shows promise in triple-negative breast cancer

Israeli biotech Ayala Pharmaceuticals has just added $30 million in a Novartis-backed series B round. As preclinical results have shown, the money could be used on clinical testing of its lead drug AL101 in triple-negative breast cancer (TNBC).